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Abstract
Cardiac complications are counted among the complications of coronavirus disease 2019 (COVID-19) in hospitalized 
patients. However, the data of non-hospitalized COVID-19 convalescents’ population is scant. This study presents a case 
of a 42-year-old woman with no medical history who underwent SARS-CoV-2 (severe acute respiratory syndrome-related 
coronavirus 2) infection at 16 March 2020. She had a fever (38 degrees Celsius) and dyspnoea that resolved after 
chloroquine administration so the patient was not hospitalized. One week later she reported palpitations and fatigue of 
functional class II New York Heart Association despite negative repeated polymerase chain reaction results (23rd March, 
1st April). Within 6 weeks she was referred to a cardiologist. The laboratory test results revealed slightly increased 
high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide. On electrocardiogram (ECG), single 
ventricular extrasystoles of right bundle branch block shape were observed. 24-hrs ECG Holter monitoring revealed 
additionally symptomatic periods of bigeminy and 4.2 thousands of ventricular extrasystoles. The cardiac magnetic 
resonance showed typical post-inflammatory myocardial changes with no active inflammation. No pharmacotherapy 
was applied. The symptoms have ceased. In the 4th month, 24-hrs ECG Holter revealed the recovery from arrhythmia. 
The presented case showed that long-term medical observation is worth to be considered even for non-hospitalized 
patients with a mild course of SARS-CoV-2 infection.
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death [1]. Yet, the late manifestation of COVID-19 CV 
sequelae has been noticed [2, 3]. They are presumed to 
be caused by cytokine storm as in other viral infections. 
The precise number of previously hospitalized COVID-19 
patients with cardiac complications is unknown. However, 
the bigger is non-hospitalized COVID-19 population and 
the long-term data of non-hospitalized COVID-19 survivors 
including cardiac complication is still missing [4].
Introduction
In the pandemic target of research is to evaluate cardio-
vascular (CV) effects. Among coronavirus disease 2019 
(COVID-19) hospitalized patients in 7–23% developed 
a myocardial injury. Its symptoms vary from mild manife-
station such as fatigue or dyspnea, through chest pain or 
tachycardia, up to cardiogenic shock or sudden cardiac 
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present. 24-hrs ECG Holter monitoring revealed sinus 
rhythm, 4.2 thousands of ventricular extrasystoles with 
symptomatic periods of bigeminy and also 597 single su-
praventricular extrasystoles (Figure 1).
The pulmonary computed tomography (CT) did not de-
tect any abnormalities. However, the cardiac magnetic re-
sonance (CMR), performed 60 days after positive PCR, sho-
wed the late mesocardial and subepicardial enhancement 
typical of myocarditis but without signs of active inflamma-
tion (Figure 2). Left ventricular ejection fraction was 64%. 
The patient had no pharmacotherapy.
On the second visit after 3 months from positive PCR, 
the patient reported alleviation of palpitation. In the 
4th month, 24-hrs ECG Holter monitoring revealed the re-
covery from ventricular arrhythmia.
Control CMR was scheduled to be performed within 
6 months.
Discussion
The major part of literature about COVID-19 is considering 
solely the hospitalized population and is mostly focused on 
acute respiratory syndrome and multiorgan dysfunction [5]. 
Nevertheless, the CV complications of SARS-CoV-2 infection 
are gaining more and more medical attention (Table 1) [6]. 
Case report
A 42-year-old female patient with no medical history un-
derwent SARS-CoV-2 (severe acute respiratory syndrome-
-related coronavirus 2) infection at 16st March 2020 
(polymerase chain reaction [PCR] positive result). The 
patient had a fever (38 degrees Celsius) and dyspnoea. 
Chloroquine was administered for 6 days — 500 mg/day, 
with significant clinical improvement (resolution of dys-
pnoea and fever). She was not hospitalized. One week later 
there was the onset of palpitations, fatigue, and functional 
class II New York Heart Association (NYHA). However, PCR 
results were twice negative (23rd March, 1st April).
After 6 weeks she was referred to a cardiologist due 
to dyspnoea and palpitations. The outcomes of laborato-
ry tests revealed slightly increased concentration of high-
sensitivity cardiac troponin T (hs-cTnT) 32 ng/L (norm 
9–22 ng/L) and natriuretic peptide [N-terminal pro-B-
type natriuretic peptide (NT-proBNP)] 184 pg/mL (norm 
≤ 125 pg/mL). The other laboratory parameters were in 
normal ranges, including lymphocytes 2.13 × 103 µL, C-re-
active protein (CRP) — 28.3 nmol/L (norm ≤ 76.19 nmol/L) 
and D-dimer — 230 μg/L (norm < 500 μg/L).
On electrocardiogram (ECG) at rest, single ventricu-
lar extrasystoles of right bundle branch block shape were 
Figure 1. 24-hrs electrocardiogram (ECG) Holter — single ventricular extrasystoles of right bundle branch block shape
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While hypertension, diabetes and coronary artery disease 
are associated with poor COVID-19 prognosis, Polish 
authors [7] have recently observed that only senior age, 
CRP and National Early Warning Score (NEWS) ≥ 2 were 
risk factors for death in patients with comorbidities. On 
the other hand, Chinese author [8] reported that fulminant 
myocarditis could cause even 7% of COVID-19-related 
deaths but the ratio may be overestimated due to lack of 
confirmatory diagnoses. Although the majority of studies 
is referring to acute conditions associated with coexisting 
CV risk factor or disease, the cases of myocardial injury 
without previous CV history are also reported. In general, 
any comorbidities are suspected to increase the risk of 
hospitalization in patients with COVID-19, but it remains 
uncertain whether they emphasize patients’ susceptibility 
to infection or not [9]. Moreover, the incidence of myocardial 
injury seems to be comparable both in patients with high 
and with a low prevalence of pre-existing CV disease [10].
At least, there is insufficient information about pos-
sible sequelae or treatment of non-hospitalized patients 
with a mild course of COVID-19. Though, it is supposed 
that almost 30% of these patients may need subsequent 
hospitalization [11]. Additionally, pulmonary embolism (PE) 
seemed to be the most studied COVID-19 complication in 
outpatients. Alharthy et al. [12] reported two cases of non-
hospitalized asymptomatic patients during SARS-CoV-2 in-
fection who presented with PE 20 and 35 days later. Simi-
larly, Gervaise et al. [13] identified CT scans finding PE in 
18% of 72 non-hospitalized patients.
Documented cases of myocarditis caused by COVID-19 
in patients without prior pneumonia or those who over-
come COVID-19 indicate the risk of late-onset of car-
diac complications, regardless of the severity of the 
COVID-19 symptoms [2]. The course of myocarditis can 
be mild to severe, or even fulminant and requiring a heart 
transplant. Furthermore, it is important to remember that 
COVID-19 symptoms may impose symptoms of myocarditis 
in course of COVID-19 [1].
COVID-19 related myocardial injury should be suspect-
ed in elevated troponins, as Inciardi et al. [2] presented 
in their case of a 53-year-old woman. The patient showed 
a positive PCR test for COVID-19 and was admitted to the 
cardiac care unit. She reported severe fatigue 2 days be-
fore the hospitalization as well as having high fever and 
cough that occurred the week before. However, she denied 
Table 1. Cardiac outcomes in hospitalized coronavirus disease 
2019 (COVID-19) patients based on meta-analysis (by Kunutsor 
et al. [10])




ACS 2 (N = 101) 6.2
Arrhythmia 6 (N = 867) 9.3
Cardiac arrest 2 (N = 187) 5.7
Cardiac injury 11 (N = 2,028) 16.3
DIC 2 (N = 359) 5.6
HF 4 (N = 820) 17.6
ACS — acute coronary syndrome; DIC — disseminated intravascular coagulation; HF — heart failure
Figure 2A, B. Cardiac magnetic resonance — late gadolinium-enhanced images in sagittal and frontal planes: mesocardial enhancement of 
basal and middle intraventricular septum segments and also subepicardial enhancement of basal and middle parts of the inferior myocar-
dial segment between right and left ventricle
A B
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chest pain, dyspnoea and further cardiovascular symp-
toms. Myocarditis was confirmed on CMR a week after 
the onset of symptoms and was accompanied by an in-
creased level of NT-proBNP (5647 pg/mL; reference range 
< 300 pg/mL) and hs-cTnT level (0.24 ng/mL; reference 
range < 0.01 ng/mL) at admission. At the time of CMR per-
forming the level of hs-cTnT was 0.63 ng/mL. On the oth-
er hand, Huang et al. [14] reported in 26 young patients, 
from who 22 recovered from moderate COVID-19 pneu-
monia, the results of troponin levels and CMR. Among this 
population only 8% of patients had prior CV history, 88% 
presented palpitation at admission. Surprisingly, only half 
of the patients had elevated hs-cTnI during hospitaliza-
tion, which has normalized at the time when CMR was 
performed, an average of 47 days [interquartile range 
(IQR): 36 to 58 days] from symptoms onset and signs of 
myocardial injuries, such as increased T2 signal and/or 
positive LGE were presented in 15 (58%) patients. In 
14 (54%) patients myocardial oedema was identified as 
a symptom of an active inflammatory process.
It is well known that troponin is elevated in a large 
number of diseases and also in the multiorgan com-
plication in COVID-19, so in myocardial injury the gold 
standard is CMR. Puntmann et al. [3] in the first pro-
spective observational cohort study of 100 unselected 
COVID-19 survivors identified from the University Hospi-
tal Frankfurt COVID-19 Registry, who underwent mild or 
moderate COVID-19, reported in 67% no need of hospi-
talization, and screened the patients for the presence 
of myocardial injury. The median time interval between 
COVID-19 diagnosis and CMR with T1 and T2 mapping 
was 71 days. A number of 78 patients lately recovered 
from COVID-19 occurred to have abnormal CMR results, 
including at least one of the following: raised myocardial 
native T1 (N = 73), raised myocardial native T2 (N = 60), 
myocardial LGE (N = 32), or pericardial enhancement 
(N = 22). On a contrary to Huang et al. study, 71% of 
patients had elevated troponin (median 4.9 pg/mL, 
IQR 3.0 to 6.9 pg/mL) at the time of CMR. Important-
ly, compared with a healthy control group and CV risk-
factors matched controls, the patients who underwent 
COVID-19 infection, presented lower left ventricular (in 
mean 57%) and right ventricular (in mean 54%) ejection 
fraction. CMR occurs to be a quantitative method allow-
ing to determine the percentage of myocardial damage 
(mapping T1 and T2), repeatable, valuable for monitor-
ing the course of the disease and the effects of therapy. 
Local fibrosis detected by late gadolinium enhancement 
(LGE) is a common finding in patients who have had vi-
ral myocarditis. Gräni et al. [15] found that the risk of 
the following CV complications was slightly altered by 
the presence of LGE with annual CV events [hazard ratio 
(HR): 2.22; 95% confidence interval (CI): 1.47 to 3.35; 
p < 0.001]. Subsequently, inflammation and fibrosis of 
the myocardium may take part in disease progression to 
heart failure (HF). The data on COVID-19 related myocar-
ditis is still limited. However, considering the inflamma-
tory nature of COVID-19 together with the myocardial in-
flammation and myocardial fibrosis as HF pathogenesis, 
future development of HF is expected. Therefore, appro-
priate heart imaging techniques must be implemented.
Viral infections are considered possible triggers of myo-
carditis and consequently of arrhythmias [9]. Two patho-
physiologic mechanisms are described in myocarditis 
due to SARS-Cov-2 infection: the cytokine storm and the 
virus affinity for angiotensin-converting enzyme 2 (ACE2) 
[1]. Although transmembrane ACE2 allows the virus to in-
vade host cells including endothelial cells and pericytes 
that may result in endothelitis and important microvascu-
lar or macrovascular dysfunction [9]. Attention is drawn 
mostly to fulminant myocarditis with no initial respiratory 
symptoms and with rapid clinical progression requiring 
hospitalization [16–18]. Hu et al. [16] described a case 
of acute HF due to fulminant myocarditis in a 37-year-old 
man without comorbidities, whose levels of hs-cTnT was 
more than 10,000 ng/L and NT-proBNP of 21,025 ng/L. 
Additionally, his left ventricular ejection fraction was 27%. 
He was successfully treated with methylprednisolone and 
immunoglobulin. Whereas, Paul et al. [17] reported a case 
of acute myocarditis as the main manifestation of CO-
VID-19 in a 35-year-old man without comorbidities, who 
presented with a level of hs-cTnT up to 2,885 ng/L and 
typical image of myocarditis in CMR even though his sys-
tolic function was normal and there was no pericardial ef-
fusion. Simple cardiological treatment with ramipril and 
bisoprolol sufficed for the patient’s recovery. Any of the au-
thors, however, did not mention the patient’s follow-up. It is 
thought that important serum troponin elevation in course 
of SARS-CoV-2 infection might be related as well to myo-
cardial injury as to multiple organ damage. Thus, neither 
hs-cTnT nor NT-proBNP is sufficient in diagnosing of myo-
carditis [1]. Nevertheless, for elevated troponin levels the 
risk of in-hospital mortality induced by COVID-19 increases 
4 times [19]. Other biomarkers warning about significant 
COVID-19 complications are among others increased lac-
tate dehydrogenase (LDH) level in case of secondary liver 
damage or increased creatinine level and decreased glo-
merular filtration rate in case of secondary kidney damage 
[4]. The details of biomarkers in COVID-19 are summarized 
in the expert opinion of the Heart Failure Working Group of 
the Polish Cardiac Society [4].
In the more advanced clinical stage of myocardial injury 
in myocarditis as a cardiac shock, the American Heart As-
sociation (AHA) guidelines [20] and other statements of the 
experts suggest that in initial management inotropes and 
vasopressors as well as mechanical ventilation need to be 
administered. However, the usage of intravenous immuno-
globulins, as well as corticosteroids, is not recommended 
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on account of their inefficiency in myocarditis [21]. Where-
as, the described case in this report provided arrhythmia 
in course of subacute myocarditis as a mild secondary in-
flammatory response to SARS-CoV-2 infection with no need 
for pharmacotherapy.
In the meantime, work is still underway to improve 
COVID-19 vaccines. The first vaccine available on the mar-
ket was the Pfizer-BioNTech COVID-19 Vaccine® authorized 
by the U.S. Food and Drug Administration (FDA) for emer-
gency use under an Emergency Use Authorization (EUA) 
to prevent COVID-19 for use in individuals of minimum 
16 years-old. The in vitro capacity of sera immunized with 
the Pfizer-BioNTech COVID-19 Vaccine® for neutralization 
of SARS-CoV-2 with key mutations present in the United 
Kingdom (U.K.) and South Africa variants has been recent-
ly studied and the preliminary results are promising [22].
The treatment of SARS-CoV-2 infection with chloroquine 
or hydroxychloroquine was supposed to be effective at the 
beginning of the pandemic in Europe, however, it is no lon-
ger recommended. Recently hydroxychloroquine has been 
found unsuccessful in symptom severity reduction and in 
lowering the risk of disease progression in outpatients with 
mild COVID-19 [23, 24]. Additionally neither hydroxychloro-
quine nor chloroquine are not approved by the FDA for the 
treatment of COVID-19 because of insufficient antiviral ef-
fect and serious side effects outweighing the known and 
potential benefits of these drugs [25]. The list of potential 
so-far known drugs, that are used in SARSCov-2 infection, 
is presented in Table 2. Nevertheless, even if the treatment 
of SARS-CoV-2 infection with chloroquine is thought to be 
possibly of arrhythmogenic potential, it has been proven 
only for long time treatment with a high cumulative dose [9].
The presented case showed the arrhythmia as the 
main manifestation of myocarditis. Due to the receding 
symptoms of arrhythmia and its mild form in the Holter 
ECG monitoring, there was no treatment administered. 
This case aimed to raise awareness of the potential risk of 
HF development despite the recovery from arrhythmia [1].
The myocardial injury may be irrespective of the seve-
rity of the COVID-19 course and airway involvement, regar-
dless of the patient’s age, and may also occur in young 
people. Subclinical cardiac injury may result in the deve-
lopment of HF in further observation. The method of cho-
ice for identifying damage is CMR (features of inflamma-
tion, oedema, fibrosis, ischemia), other standard diagno-
stic methods used in cardiology [ECG, echocardopgraphy 
(ECHO)] allow to document changes in the heart when they 
are more advanced. CMR occurs to be a method of detec-
ting early and subclinical damage when other methods fail.
Conclusions
The case presented a mild course of myocarditis after 
SARS-CoV-2 infection in a non-hospitalized 42-year-old 
patient with no prior history of CV diseases and no burden 
of CV risk factors with the subsequent development of 
ventricular arrhythmia.
The pandemic is not coming to the end and the number 
of patients, including those with complications, continues 
to grow. While we have no control over non-hospitalized 
patients, the increased burden of cardiac complication in-
cluding myocarditis should be considered in future rese-
arch. Thus, long-term observation is worth to be applied 
for non-hospitalized COVID-19 survivors.
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Table 2. Potential coronavirus disease 2019 (COVID-19) therapies
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Intravenous 482 NCT04381936 Dyslipidaemia
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Covalescent plasma Beneficial among 
infected patients
Intravenous 35322 NCT04338360 Thrombotic events
Lopinavir/ritonavir Not satisfactory Oral 1596 NCT04381936 Concomitant admi-
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Streszczenie
Wśród powikłań choroby koronawirusowej (COVID-19) u hospitalizowanych pacjentów wymienia się między innymi 
powikłania sercowe. Jednak dane dotyczące powikłań w populacji niehospitalizowanych ozdrowieńców po COVID-19 
są nieliczne. W niniejszej pracy przedstawiono przypadek 42-letniej kobiety bez chorób współistniejących, u której 
16 marca 2020 doszło do zakażenia SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2). Pacjentka 
zgłaszała gorączkę (38°C) i duszność, które ustąpiły po podaniu chlorochiny, bez konieczności hospitalizacji. Tydzień 
później pojawiło się uczucie kołatania serca i zmęczenie w II klasie czynnościowej według skali New York Heart Asso-
ciation. Wyniki kolejnych testów metodą reakcji łańcuchowej polimerazy (PCR) (23 marca, 1 kwietnia) były ujemne. Po 
6 tygodniach pacjentka została przyjęta do kardiologa. Wyniki badań laboratoryjnych wykazały nieznaczny wzrost stężeń 
sercowej troponiny T oznaczonej metodą wysokoczułą oraz N-końcowego fragmentu propetydu natriuretycznego typu B. 
W elektrokardiogramie (EKG) zaobserwowano pojedyncze ekstrasystolie komorowe o kształcie bloku prawej odnogi 
pęczka Hisa. W 24-godzinnym zapisie EKG metodą Holtera stwierdzono ponadto objawowe okresy bigeminii i 4,2 tys. 
ekstrasystolii komorowych. Rezonans magnetyczny serca uwidocznił typowe pozapalne zmiany w mięśniu sercowym bez 
cech aktywnego zapalenia. U pacjentki nie stosowano farmakoterapii. Objawy ustąpiły, a kontrolny 24-godzinny zapis 
EKG metodą Holtera w 4. miesiącu po infekcji wykazał ustanie arytmii. Przedstawiony przypadek ukazuje potrzebę 
rozważenia długoterminowej obserwacji medycznej pacjentów niehospitalizowanych, nawet po łagodnym przebiegu 
zakażenia SARS-CoV-2.
Słowa kluczowe: infekcja SARS-CoV-2, arytmia, zapalenie mięśnia sercowego, niehospitalizowany ozdrowieniec
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